Fulgent Genetics (FLGT) Income from Continuing Operations (2015 - 2026)

Fulgent Genetics has disclosed Income from Continuing Operations across 12 years of filings, most recently posting 25278000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 25278000.0, down 112.01% year-over-year; the trailing twelve-month figure through Mar 2026 was 14331000.0 (up 61.01% YoY), and the FY2025 annual result was 1006000.0, up 97.4% from the prior year.
• Income from Continuing Operations came in at 25278000.0 for Q1 2026 at Fulgent Genetics, down from 36975000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 153557000.0 in Q1 2022 to a low of 25278000.0 in Q1 2026.
• The 5-year median for Income from Continuing Operations is 11600000.0 (2023), against an average of 3569588.24.
• Across the five-year window, Income from Continuing Operations plunged 1100.74% in 2023 and soared 3631.52% in 2025, its largest moves.
• Fulgent Genetics' Income from Continuing Operations stood at 24076000.0 in 2022, then soared by 202.09% to 24580000.0 in 2023, then tumbled by 104.26% to 1047000.0 in 2024, then jumped by 3631.52% to 36975000.0 in 2025, then tumbled by 168.37% to 25278000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 25278000.0 (Q1 2026), 36975000.0 (Q4 2025), and 6809000.0 (Q3 2025), per Business Quant data.